KR20220128382A - 만성 폐쇄성 폐질환을 관리하기 위한 조성물 - Google Patents

만성 폐쇄성 폐질환을 관리하기 위한 조성물 Download PDF

Info

Publication number
KR20220128382A
KR20220128382A KR1020227027330A KR20227027330A KR20220128382A KR 20220128382 A KR20220128382 A KR 20220128382A KR 1020227027330 A KR1020227027330 A KR 1020227027330A KR 20227027330 A KR20227027330 A KR 20227027330A KR 20220128382 A KR20220128382 A KR 20220128382A
Authority
KR
South Korea
Prior art keywords
chronic obstructive
obstructive pulmonary
pulmonary disease
increased
emphysema
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227027330A
Other languages
English (en)
Korean (ko)
Inventor
무하메드 마지드
칼야남 나가브후스하남
사랑 바니
안잘리 판데이
Original Assignee
새미-사빈사 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 새미-사빈사 그룹 리미티드 filed Critical 새미-사빈사 그룹 리미티드
Publication of KR20220128382A publication Critical patent/KR20220128382A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227027330A 2020-01-17 2021-01-16 만성 폐쇄성 폐질환을 관리하기 위한 조성물 Pending KR20220128382A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062962343P 2020-01-17 2020-01-17
US62/962,343 2020-01-17
US202063126920P 2020-12-17 2020-12-17
US63/126,920 2020-12-17
PCT/US2021/013763 WO2021146648A1 (en) 2020-01-17 2021-01-16 Compositions for managing chronic obstructive pulmonary disease

Publications (1)

Publication Number Publication Date
KR20220128382A true KR20220128382A (ko) 2022-09-20

Family

ID=76856592

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227027330A Pending KR20220128382A (ko) 2020-01-17 2021-01-16 만성 폐쇄성 폐질환을 관리하기 위한 조성물

Country Status (9)

Country Link
US (1) US11925606B2 (enExample)
EP (1) EP4090340B1 (enExample)
JP (1) JP7746272B2 (enExample)
KR (1) KR20220128382A (enExample)
CN (1) CN115175672B (enExample)
AU (1) AU2021207536B2 (enExample)
BR (1) BR112022014114A2 (enExample)
CA (1) CA3164013A1 (enExample)
WO (1) WO2021146648A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023554642A (ja) * 2020-12-17 2023-12-28 サミ－サビンサ グループ リミテッド ビスデメトキシクルクミン組成物の抗肥満能
WO2022203721A1 (en) * 2021-03-25 2022-09-29 Muhammed Majeed Compositions and methods for inhibiting proteolytic activation of viruses
RS20220433A1 (sr) 2022-05-11 2023-11-30 Milan Prokin Višeciljni antivirusni dodatak ishrani

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20100179103A1 (en) * 2008-07-21 2010-07-15 Ketan Desai Curcumin cyclodextrin combination for preventing or treating various diseases
US8486909B2 (en) * 2009-06-24 2013-07-16 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
EP2475380A1 (en) * 2009-09-11 2012-07-18 Protaffin Biotechnologie AG Composition for treatment of cxcl8-mediated lung inflammation
WO2012047674A2 (en) * 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
ITMI20132169A1 (it) * 2013-12-20 2015-06-21 Thompson S R L Composizione per la prevenzione ed il trattamento della bpco e della sintomatologia correlata
JP2017516764A (ja) * 2014-04-18 2017-06-22 オムニアクティブ ヘルス テクノロジーズ リミテッド クルクミン組成物及びその使用
WO2016145159A1 (en) * 2015-03-10 2016-09-15 The Research Foundation For The State University Of New York Chemically modified curcumins for use in the production of lipoxins
JP6688009B2 (ja) * 2015-04-15 2020-04-28 長谷川　浩二 酸化変性ｌｄｌ複合体抑制剤
CN105998043B (zh) * 2016-07-01 2018-11-27 吉林大学 槐属双苷在制备防治慢性阻塞性肺疾病药物中的应用

Also Published As

Publication number Publication date
US11925606B2 (en) 2024-03-12
CN115175672A (zh) 2022-10-11
AU2021207536B2 (en) 2025-04-10
CA3164013A1 (en) 2021-07-22
NZ790708A (en) 2025-05-02
CN115175672B (zh) 2024-07-02
WO2021146648A1 (en) 2021-07-22
BR112022014114A2 (pt) 2022-09-13
JP2023512489A (ja) 2023-03-27
AU2021207536A1 (en) 2022-08-11
US20210220290A1 (en) 2021-07-22
EP4090340A1 (en) 2022-11-23
EP4090340B1 (en) 2026-05-06
EP4090340A4 (en) 2024-02-21
JP7746272B2 (ja) 2025-09-30

Similar Documents

Publication Publication Date Title
US11925606B2 (en) Compositions for managing chronic obstructive pulmonary disease
Xiong et al. PM2. 5-induced lung injury is attenuated in macrophage-specific NLRP3 deficient mice
Nikhat et al. Overview of Covid-19; its prevention and management in the light of Unani medicine
Choudhury et al. Role of inflammation and oxidative stress in the pathology of ageing in COPD: potential therapeutic interventions
ARAKAWA et al. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing
McMillan et al. Prolonged allergen challenge in mice leads to persistent airway remodelling
Kang et al. Dai-Huang-Fu-Zi-Tang alleviates pulmonary and intestinal injury with severe acute pancreatitis via regulating aquaporins in rats
Lee et al. Kynurenic acid attenuates pro-inflammatory reactions in lipopolysaccharide-stimulated endothelial cells through the PPARδ/HO-1-dependent pathway
Lyu et al. Anti‐inflammatory effects of reticuline on the JAK2/STAT3/SOCS3 and p38 MAPK/NF‐κB signaling pathway in a mouse model of obesity‐associated asthma
Shin et al. Anti-allergic effect of bee venom in an allergic rhinitis mouse model
Xia et al. Yu Gan Long reduces rat liver fibrosis by blocking TGF-β1/Smad pathway and modulating the immunity
Peng et al. Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019
Lee et al. Distribution of RANTES and interleukin-5 in allergic nasal mucosa and nasal polyps
US20200316133A1 (en) Fat and medical uses thereof
Lee et al. Anti-asthmatic effects of phenylpropanoid glycosides from Clerodendron trichotomum leaves and Rumex gmelini herbes in conscious guinea-pigs challenged with aerosolized ovalbumin
Liang et al. Salvianolic acid B in fibrosis treatment: a comprehensive review
Günel et al. Inhibitory effect of Pycnogenol® on airway inflammation in ovalbumin-induced allergic rhinitis
Wang et al. Phosphocreatine alleviates liver fibrosis in diabetic mice by targeting TGF-β/Smad and α-SMA pathways
Kinhult et al. Pituitary adenylate cyclase‐activating polypeptide, effects in the human nose
US12594316B2 (en) Plant composition, traditional Chinese medicine composition and use thereof
Xu et al. Xiangsha Liujunzi Decoction restores mitochondrial function and ameliorates chronic ulcerative colitis by regulating the PI3K/AKT/Nrf2 and AMPK/SIRT1/PGC-1α signaling pathways
CN104622886A (zh) 烟酰胺核糖在制备治疗非酒精性脂肪性肝炎的药物中的应用
Ishibashi et al. Ibudilast suppresses MUC5AC mucus production through inhibition of ERK1/2 phosphorylation
Shehata et al. Morin attenuates sepsis-induced acute kidney injury by regulating inflammatory responses, oxidative stress and tubular regeneration (morin and sepsis-induced acute kidney injury)
KR20120009667A (ko) 난백알부민을 유효성분으로 포함하는 알레르기 질환 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902